國立高雄大學圖資館 |

Language: English

Back

Resistance to targeted therapies in ...

Cairo, Mitchell S.

Resistance to targeted therapies in lymphomas

Record Type:	Electronic resources : Monograph/item
Title/Author:	Resistance to targeted therapies in lymphomasedited by Ana C. Xavier, Mitchell S. Cairo.
other author:	Xavier, Ana C.
Published:	Cham :Springer International Publishing :2019.
Description:	xx, 210 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
Subject:	LymphomasTreatment.
Online resource:	https://doi.org/10.1007/978-3-030-24424-8
ISBN:	9783030244248$q(electronic bk.)

Resistance to targeted therapies in lymphomas
Resistance to targeted therapies in lymphomas[electronic resource] /edited by Ana C. Xavier, Mitchell S. Cairo. - Cham :Springer International Publishing :2019. - xx, 210 p. :ill., digital ;24 cm. - Resistance to targeted anti-cancer therapeutics,v.212196-5501 ;. - Resistance to targeted anti-cancer therapeutics ;v.4..

Mechanisms of Glucocorticoid Response and Resistance in Lymphoid Malignancies -- Resistance to Monoclonal Antibody Therapeutics in Lymphoma -- Resistance to Antibody-Drug Conjugate -- Resistance to Proteasome Inhibitor Therapy in Non-Hodgkin Lymphoma -- Resistance to Histone Deacetylase Inhibitors in the Treatment of Lymphoma -- Resistance to Bruton's Tyrosine Kinase Signaling Pathway Targeted Therapies -- Resistance to Checkpoint Blockade Inhibitors and Immunomodulatory Drugs -- Resistance to Bispecific T-cell Engagers and Bispecific Antibodies -- Resistance to Chimeric antigen receptor T-cell therapy -- Index.

This volume will review different classes of "target" drugs that have been developed, approved, or are under investigation in the field of lymphoma therapy. The discussion will not only be on the understanding of the mechanisms of action or clinical response of those agents, but also help the reader to understand the nature of lymphoma biology in patients who relapse or are refractor after exposure to those drugs. Contributors will discuss what is currently known about mechanisms of tumor-related or host-related resistance, and how to overcome this resistance. This understanding is crucial given the dismal outcomes of patients with relapsed or refractory lymphomas. The book provides a unique opportunity to review and reflect on the recent successes and pitfalls of the modern lymphoma therapy era.

ISBN: 9783030244248$q(electronic bk.)

Standard No.: 10.1007/978-3-030-24424-8doiSubjects--Topical Terms:

520176
Lymphomas
--Treatment.

LC Class. No.: RC280.L9 / R475 2019

Dewey Class. No.: 616.99446

Resistance to targeted therapies in lymphomas
LDR:02504nmm a2200337 a 4500 001 566248
003 DE-He213
005 20191217142447.0
006 m d
007 cr nn 008maaau
008 200429s2019 gw s 0 eng d
020 $a 9783030244248$q(electronic bk.)
020 $a 9783030244231$q(paper)
024 7 $a 10.1007/978-3-030-24424-8 $2 doi
035 $a 978-3-030-24424-8
040 $a GP $c GP
041 0 $a eng
050 4 $a RC280.L9 $b R475 2019
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.99446 $2 23
090 $a RC280.L9 $b R433 2019
245 0 0 $a Resistance to targeted therapies in lymphomas $h [electronic resource] / $c edited by Ana C. Xavier, Mitchell S. Cairo.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2019.
300 $a xx, 210 p. : $b ill., digital ; $c 24 cm.
490 1 $a Resistance to targeted anti-cancer therapeutics, $x 2196-5501 ; $v v.21
505 0 $a Mechanisms of Glucocorticoid Response and Resistance in Lymphoid Malignancies -- Resistance to Monoclonal Antibody Therapeutics in Lymphoma -- Resistance to Antibody-Drug Conjugate -- Resistance to Proteasome Inhibitor Therapy in Non-Hodgkin Lymphoma -- Resistance to Histone Deacetylase Inhibitors in the Treatment of Lymphoma -- Resistance to Bruton's Tyrosine Kinase Signaling Pathway Targeted Therapies -- Resistance to Checkpoint Blockade Inhibitors and Immunomodulatory Drugs -- Resistance to Bispecific T-cell Engagers and Bispecific Antibodies -- Resistance to Chimeric antigen receptor T-cell therapy -- Index.
520 $a This volume will review different classes of "target" drugs that have been developed, approved, or are under investigation in the field of lymphoma therapy. The discussion will not only be on the understanding of the mechanisms of action or clinical response of those agents, but also help the reader to understand the nature of lymphoma biology in patients who relapse or are refractor after exposure to those drugs. Contributors will discuss what is currently known about mechanisms of tumor-related or host-related resistance, and how to overcome this resistance. This understanding is crucial given the dismal outcomes of patients with relapsed or refractory lymphomas. The book provides a unique opportunity to review and reflect on the recent successes and pitfalls of the modern lymphoma therapy era.
650 0 $a Lymphomas $x Treatment. $3 520176
650 0 $a Drug resistance. $3 569293
650 1 4 $a Cancer Research. $3 273660
700 1 $a Xavier, Ana C. $3 851857
700 1 $a Cairo, Mitchell S. $3 851858
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
830 0 $a Resistance to targeted anti-cancer therapeutics ; $v v.4. $3 711051
856 4 0 $u https://doi.org/10.1007/978-3-030-24424-8
950 $a Biomedical and Life Sciences (Springer-11642)